Heartbeam

Heartbeam ROE

The Return on Equity (ROE) of Heartbeam (BEAT) as of Oct 21, 2026 is -807.34 %. In the previous year, Return on Equity (ROE) was -1,175.82 % — a change of -31.34% (higher).

ROE

-807.34 %

YoY

-31.34%

Last updated:

In 2025, Heartbeam's return on equity (ROE) was -807.34 %, a -31.34% increase from the -1,175.82 % ROE in the previous year.

The Heartbeam ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
13.79 USD
Jan 1, 2019
20.87 USD
Jan 1, 2020
28.17 USD
Jan 1, 2021
-33.02 USD
Jan 1, 2022
-540.31 USD
Jan 1, 2023
-91.86 USD
Jan 1, 2024
-1,175.82 USD
Jan 1, 2025
-807.34 USD
The Heartbeam ROE history
YEARROEYoY
-807.34 %-31.34%
-1,175.82 %+1,180.07%
-91.86 %-83.00%
-540.31 %+1,536.31%
-33.02 %-217.21%
28.17 %+34.95%
20.87 %+51.36%
13.79 %-316.74%
-6.36 %-116.54%
38.47 %+293.20%
9.78 %-163.61%
-15.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Heartbeam Stock analysis

What does Heartbeam do? HeartBeam, Inc. generates revenue through its proprietary VECG technology platform, which includes two patented products: HeartBeam AIMI and HeartBeam AIMIGo. HeartBeam AIMI is software designed for acute care settings, offering 3D comparison of baseline and symptomatic 12-lead ECG to detect heart attacks. HeartBeam AIMIGo is a credit card-sized 12-lead ECG device paired with a smartphone app and cloud-based diagnostic software for remote heart attack detection. The company targets healthcare facilities and remote monitoring segments, focusing on cardiovascular diagnostic solutions for both in-hospital and out-of-hospital settings. HeartBeam AIMI is sold to acute care providers such as hospitals and emergency departments, while HeartBeam AIMIGo serves patients and remote healthcare services seeking continuous cardiac monitoring. The firm's revenue streams derive from the commercialization of these two products, leveraging its patented VECG technology to provide higher resolution ambulatory ECG solutions. The company's focus on detecting and monitoring cardiac disease outside traditional healthcare facilities drives its product development and sales strategy. HeartBeam Inc. operates in the cardiovascular diagnostic technology sector, with its products designed to enable cardiac disease detection both inside and outside healthcare facilities. The firm's VECG platform allows for 3D vector imaging of cardiac electrical activity, enhancing diagnostic capabilities beyond standard ECG methods. Revenue is generated through the sale of software, devices, and cloud-based diagnostic systems tailored to specific healthcare environments and remote monitoring needs. Heartbeam is one of the most popular companies on Eulerpool.

ROE Details

Decoding Heartbeam's Return on Equity (ROE)

Heartbeam's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Heartbeam's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Heartbeam's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Heartbeam’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Heartbeam stock

Return on Equity (ROE) of Heartbeam is -807.34 % in 2025.

Return on Equity (ROE) of Heartbeam changed from -1,175.82 % to -807.34 %, representing a -31.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Heartbeam since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Heartbeam with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Heartbeam

All Key Metrics — Heartbeam